Monday, August 31, 2026
ExploreSearch
Via News
Markets

New Residential Inv Stock 3.91% Up On Thursday

ViaNews Editorial Team

December 17, 2020

New Residential Inv Stock 3.91% Up On Thursday

The New York Stock Exchange ended the session with New Residential Inv rising 3.91% to $9.98 on Thursday while the New York Stock Exchange jumped 0.68% to $14,506.70.

New Residential Inv today's close was $9.98, 76.95% below its 52-week high of $17.66.

New Residential Inv's Sales

New Residential Inv's sales growth is 8.4% for the current quarter and 27.3% for the next. The company's growth estimates for the present quarter and the next is a negative 45.9% and a negative 25%, respectively.

New Residential Inv's Revenue

Year-on-year quarterly revenue growth grew by 6%, now sitting on -117.66M for the twelve trailing months.

New Residential Inv's Stock Yearly Top and Bottom Value

New Residential Inv's stock is valued at $9.98 at 16:25 EST, way under its 52-week high of $17.66 and way above its 52-week low of $2.91.

New Residential Inv's Moving Average

New Residential Inv's worth is way above its 50-day moving average of $8.84 and way higher than its 200-day moving average of $8.07.

Categories

Markets

Tags

Stock MarketStockWall StreetStock PriceStock Market NowNYSEMarket SessionNYAThe New York Stock ExchangeStock Price UpNew Residential InvNRZ
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com